A Cytochrome c-Chlorotoxin Hybrid Protein as a Possible Antiglioma Drug

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Malignant gliomas are aggressive primary brain tumors with poor patient prognosis despite current therapies.
• Cytochrome c (Cytc) has potential for glioma treatment due to its apoptosis-inducing capabilities.
• Cellular uptake of Cytc is limited, hindering its therapeutic application.

Purpose of the Study:

• To biosynthesize a hybrid cytochrome c-chlorotoxin (Cytc-CTX) protein for enhanced glioma treatment.
• To facilitate cellular uptake of Cytc into glioma cells via CTX transporters.
• To evaluate the therapeutic potential and safety of the Cytc-CTX hybrid protein.

Main Methods:

• A nucleotide sequence encoding a 1:1 ratio of Cytc and CTX, separated by a hexahistidine-tag and enterokinase cleavage site, was constructed.
• The sequence was cloned into a pBTR1 plasmid and expressed in Escherichia coli.
• The hybrid protein was purified using 2-dimensional chromatography and characterized by Western blot and mass spectrometry.

Main Results:

• The soluble hybrid Cytc-CTX protein demonstrated structural and stability similar to native human Cytc.
• The hybrid protein was effectively endocytosed into a glioma cell line.
• Cytc-CTX exhibited potent cytotoxicity against glioma cells with a favorable therapeutic index.

Conclusions:

• The biosynthesized Cytc-CTX hybrid protein is efficiently internalized by glioma cells.
• The hybrid protein displays significant antiglioma cytotoxicity.
• The facile synthesis, biocompatibility, and efficacy suggest Cytc-CTX is a promising candidate for antiglioma drug development.